Literature DB >> 17119154

Peptides targeting protein kinases: strategies and implications.

Oksana Kaidanovich-Beilin1, Hagit Eldar-Finkelman.   

Abstract

Protein kinases are important key regulators in most, if not all, biological processes and are linked with many human diseases. Protein kinases thus became attractive targets for drug design. Intracellularly active peptides that selectively interfere with kinase function and or kinase-mediated signaling pathways are potential drug compounds with therapeutic implications.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17119154     DOI: 10.1152/physiol.00022.2006

Source DB:  PubMed          Journal:  Physiology (Bethesda)        ISSN: 1548-9221


  14 in total

1.  Selectivity of docking sites in MAPK kinases.

Authors:  A Jane Bardwell; Erlynn Frankson; Lee Bardwell
Journal:  J Biol Chem       Date:  2009-02-05       Impact factor: 5.157

2.  Overexpression of atypical protein kinase C in HeLa cells facilitates macropinocytosis via Src activation.

Authors:  Ellen J Tisdale; Assia Shisheva; Cristina R Artalejo
Journal:  Cell Signal       Date:  2014-02-27       Impact factor: 4.315

3.  Probing enzymatic activity inside living cells using a nanowire-cell "sandwich" assay.

Authors:  Yu-Ran Na; So Yeon Kim; Jellert T Gaublomme; Alex K Shalek; Marsela Jorgolli; Hongkun Park; Eun Gyeong Yang
Journal:  Nano Lett       Date:  2012-12-20       Impact factor: 11.189

4.  Development of an intracellularly acting inhibitory peptide selective for PKN.

Authors:  Kazuhiro Shiga; Kentaro Takayama; Shiroh Futaki; Jessica E Hutti; Lewis C Cantley; Katsuko Ueki; Yoshitaka Ono; Hideyuki Mukai
Journal:  Biochem J       Date:  2009-12-23       Impact factor: 3.857

5.  An APP inhibitory domain containing the Flemish mutation residue modulates gamma-secretase activity for Abeta production.

Authors:  Yuan Tian; Bhramdeo Bassit; Deming Chau; Yue-Ming Li
Journal:  Nat Struct Mol Biol       Date:  2010-01-10       Impact factor: 15.369

6.  Cell-permeable carboxyl-terminal p27(Kip1) peptide exhibits anti-tumor activity by inhibiting Pim-1 kinase.

Authors:  Daisuke Morishita; Miho Takami; Seiko Yoshikawa; Ryohei Katayama; Shigeo Sato; Mutsuko Kukimoto-Niino; Takashi Umehara; Mikako Shirouzu; Kazuhisa Sekimizu; Shigeyuki Yokoyama; Naoya Fujita
Journal:  J Biol Chem       Date:  2010-11-09       Impact factor: 5.157

Review 7.  Opportunities to Target Specific Contractile Abnormalities with Smooth Muscle Protein Kinase Inhibitors.

Authors:  Annegret Ulke-Lemée; Justin A MacDonald
Journal:  Pharmaceuticals (Basel)       Date:  2010-05-26

8.  Glycogen Synthase Kinase 3 Inactivation Compensates for the Lack of CD28 in the Priming of CD8+ Cytotoxic T-Cells: Implications for anti-PD-1 Immunotherapy.

Authors:  Alison Taylor; Christopher E Rudd
Journal:  Front Immunol       Date:  2017-12-11       Impact factor: 7.561

9.  Neuroprotective effect of novel cognitive enhancer noopept on AD-related cellular model involves the attenuation of apoptosis and tau hyperphosphorylation.

Authors:  Rita U Ostrovskaya; Yulia V Vakhitova; Uliyana Sh Kuzmina; Milyausha Kh Salimgareeva; Liana F Zainullina; Tatiana A Gudasheva; Vener A Vakhitov; Sergey B Seredenin
Journal:  J Biomed Sci       Date:  2014-08-06       Impact factor: 8.410

10.  Glycogen Synthase Kinase 3 Inactivation Drives T-bet-Mediated Downregulation of Co-receptor PD-1 to Enhance CD8(+) Cytolytic T Cell Responses.

Authors:  Alison Taylor; James A Harker; Kittiphat Chanthong; Philip G Stevenson; Elina I Zuniga; Christopher E Rudd
Journal:  Immunity       Date:  2016-02-16       Impact factor: 31.745

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.